ARDS 是引起重癥患者呼吸衰竭的主要原因, 盡管醫療技術有了很大的進步, 但對ARDS 的治療只局限在器官支持層面, 其病死率仍高達40% [ 1] 。ARDS的主要病理改變為肺泡上皮細胞和毛細血管內皮細胞受損, 通透性增加, 富含蛋白質的液體滲出積聚于肺間質和肺泡。因此促進損傷肺毛細血管內皮細胞和肺泡上皮細胞的有效修復可能是ARDS治療的關鍵所在。隨著干細胞工程學的發展, 間充質干細胞( MSC) 作為一種理想的組織修復來源, 在ARDS 治療中的應用受到越來越多的關注, 這可能為ARDS 的治療開辟一條新的途徑。
Objective To assess the quality of reporting of randomized controlled trials (RCTs) related to traditional Chinese medicine (TCM) published in the Chinese Journal of Evidence-Based Medicine by CONSORT statement and Jadad scale. Methods We handsearched the Chinese Journal of Evidence-Based Medicine to identify TCM RCTs. The revised CONSORT statement and Jadad scale combined with self-established criteria were applied. Results A total of 57 RCTs were identified of which there were 17 TCM RCTs. Some items in CONSORT checklist were completely reported in all TCM RCTs, such as abstract, inclusion and exclusion criteria, intervention, randomization sequence generation, description of statistic method, description of baseline data, outcomes and estimation, and explain results. Compared with the previous findings, there were more trials in this study to report allocation concealment, randomization implementation, use of flow chart and appliance. Only 3 RCTs (17.6%) reported acknowledgements. One RCT did not describe syndrome type of TCM, and 4 RCTs (23.5%) carried out dummy. The mean Jadad score was 4.35±1.11 in all trials, of which 11 RCTs (64.7) ranked 5 points. Conclusion The comprehensive quality of reporting of TCM RCTs published in the Chinese Journal of Evidence-Based Medicine from 2001 to 2008 has been improved. After the publication of CONSORT statement and CONSORT for traditional Chinese medicine, the quality of reporting of TCM RCTs is improved. We are looking forward to improving the CONSORT for TCM.